EIKO LIFESCIENCES LTD.

NSE : NABSE : 540204ISIN CODE : INE666Q01016Industry : ChemicalsHouse : Private
BSE55.52-0.38 (-0.68 %)
PREV CLOSE ( ) 55.90
OPEN PRICE ( ) 54.51
BID PRICE (QTY) 55.33 (75)
OFFER PRICE (QTY) 55.52 (100)
VOLUME 11980
TODAY'S LOW / HIGH ( )54.51 56.95
52 WK LOW / HIGH ( ) 46.7981.32
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2020Mar2019Mar2018
Profit Before Tax-49.35-9.980.00
Adjustment3.613.38NA
Changes In working Capital42.718.45NA
Cash Flow after changes in Working Capital-3.031.850.00
Cash Flow from Operating Activities-3.261.62NA
Cash Flow from Investing Activities-7.10-2.97NA
Cash Flow from Financing Activities9.47-5.53NA
Net Cash Inflow / Outflow-0.89-6.880.00
Opening Cash & Cash Equivalents1.138.01NA
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANA
Effect of Foreign Exchange FluctuationsNANANA
Closing Cash & Cash Equivalent0.241.13NA

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.